Simponi golimumab regulatory update

The European Commission approved Simponi golimumab from Johnson & Johnson for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate

Read the full 295 word article

How to gain access

Continue reading with a
two-week free trial.